Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics today, presented two clinical studies demonstrating the potential utility of non-invasive sampling of patients’ urine to detect and manage prostate cancer.